MedTrace Logo

In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate

NCT03059017 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-23

No results posted yet for this study

Summary

The relative bioavailability of different salbutamol sulphate inhaler formulations will be studied in healthy male subjects according to the ethical regulations of World Medical Association Declaration of Helsinki (1996) after the approval of the ethical committee, Faculty of Pharmacy, The British University in Egypt.

Conditions

  • Drug Effect
  • Pulmonary Disease

Interventions

DRUG

Salbutamol Sulphate

salbutamol sulphate packaged as aerosol

DRUG

Niosomes

Niosomes

Sponsors & Collaborators

  • British University In Egypt

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-05
Primary Completion
2017-02-05
Completion
2017-02-05
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03059017 on ClinicalTrials.gov